HAROLD L BROOKS JUNIOR
- Type
- Physician · Allopathic & Osteopathic Physicians / General Practice
- Where
- DOTHAN, AL
- NPI
- 1831157890
- Received
- $690,388 in 131 records, 2019 to 2025 ($683,266 general, $7,122 research); ownership interests with $2,561,117 invested
- As principal investigator
- $2,787,951 of research payments to others in 176 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 24 | $581 |
| 2024 | General payment | 24 | $584 |
| 2024 | Ownership or investment interest | 2 | $2,305,145 |
| 2024 | Research payment | 1 | $4,644 |
| 2023 | General payment | 16 | $328 |
| 2023 | Ownership or investment interest | 2 | $255,972 |
| 2022 | General payment | 18 | $36,898 |
| 2022 | Ownership or investment interest | 2 | $0 |
| 2022 | Research payment | 1 | $2,478 |
| 2021 | General payment | 10 | $452,069 |
| 2021 | Ownership or investment interest | 2 | $0 |
| 2020 | General payment | 4 | $82,769 |
| 2020 | Ownership or investment interest | 2 | $0 |
| 2019 | General payment | 21 | $110,034 |
| 2019 | Ownership or investment interest | 2 | $0 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| US Retina LLC | 23 | $3,240,886 | 2019–2024 |
| F. Hoffmann-La Roche AG | 2 | $7,122 | 2022–2024 |
| Genentech, Inc. | 7 | $1,350 | 2019 |
| Genentech USA, Inc. | 35 | $762 | 2019–2025 |
| ABBVIE INC. | 16 | $379 | 2022–2025 |
| Regeneron Healthcare Solutions, Inc. | 11 | $231 | 2019–2025 |
| Apellis Pharmaceuticals, Inc. | 6 | $149 | 2023–2025 |
| Allergan, Inc. | 7 | $122 | 2019–2021 |
| Astellas Pharma US Inc | 4 | $91 | 2023–2025 |
| Novartis Pharmaceuticals Corporation | 6 | $89 | 2019–2020 |
| Biogen, Inc. | 4 | $86 | 2022–2024 |
| Bausch & Lomb Americas Inc. | 4 | $81 | 2023–2025 |
| Sandoz Inc. | 2 | $69 | 2024 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 | 2025 |
| Cook Medical LLC | 1 | $32 | 2024 |
| Coherus Oncology, Inc. | 1 | $14 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Ownership or investment interest | 12 | $2,561,117 |
| Current or prospective ownership or investment interest | 10 | $377,613 |
| Acquisitions | 1 | $302,155 |
| Research payment | 2 | $7,122 |
| Food and Beverage | 103 | $2,571 |
| Travel and Lodging | 3 | $925 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | Bausch & Lomb Americas Inc. | $23 | Food and Beverage | In-kind items and services | XIPERE Drug, Ophthalmology | 2025 | |
| 2025-12-17 | Apellis Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-12-16 | Genentech USA, Inc. | $26 | Food and Beverage | In-kind items and services | Susvimo Drug, Immunology and Ophthalmology | 2025 | |
| 2025-12-10 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2025 | |
| 2025-12-04 | Mallinckrodt Hospital Products Inc. | $20 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-11-06 | Bausch & Lomb Americas Inc. | $18 | Food and Beverage | In-kind items and services | XIPERE Drug, Ophthalmology | 2025 | |
| 2025-10-22 | Mallinckrodt Hospital Products Inc. | $17 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-10-21 | Astellas Pharma US Inc | $26 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-10-16 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2025 | |
| 2025-10-07 | Genentech USA, Inc. | $31 | Food and Beverage | In-kind items and services | Susvimo Drug, Immunology and Ophthalmology | 2025 | |
| 2025-09-24 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2025 | |
| 2025-09-17 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2025 | |
| 2025-09-04 | Astellas Pharma US Inc | $22 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-08-20 | Apellis Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2025 | |
| 2025-07-09 | Genentech USA, Inc. | $29 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2025 | |
| 2025-06-12 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2025 | |
| 2025-06-10 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2025 | |
| 2025-04-17 | Apellis Pharmaceuticals, Inc. | $28 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-04-09 | Genentech USA, Inc. | $27 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2025 | |
| 2025-04-02 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2025 | |
| 2025-02-26 | Genentech USA, Inc. | $14 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2025 | |
| 2025-02-19 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2025 | |
| 2025-01-31 | Genentech USA, Inc. | $13 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2025 | |
| 2024-12-04 | Bausch & Lomb Americas Inc. | $21 | Food and Beverage | In-kind items and services | XIPERE Drug, Ophthalmology | 2024 | |
| 2024-11-20 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-11-19 | Regeneron Healthcare Solutions, Inc. | $31 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2024 | |
| 2024-11-14 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2024 | |
| 2024-11-12 | Regeneron Healthcare Solutions, Inc. | $16 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2024 | |
| 2024-10-17 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2024 | |
| 2024-10-16 | Apellis Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2024 | |
| 2024-09-30 | F. Hoffmann-La Roche AG | $4,644 | Research payment | In-kind items and services | Lucentis Biological, Ophthalmology | PDS Endophthalmitis Case Series | 2024 |
| 2024-09-18 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-08-28 | Apellis Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2024 | |
| 2024-08-08 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2024 | |
| 2024-08-07 | Regeneron Healthcare Solutions, Inc. | $20 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2024 | |
| 2024-08-01 | Cook Medical LLC | $32 | Food and Beverage | Cash or cash equivalent | COOK Device, Urology | 2024 | |
| 2024-07-24 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-07-10 | Biogen, Inc. | $26 | Food and Beverage | In-kind items and services | BYOOVIZ Biological, Ophthalmology | 2024 | |
| 2024-07-09 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2024 | |
| 2024-06-27 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2024 | |
| 2024-06-19 | Regeneron Healthcare Solutions, Inc. | $16 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2024 | |
| 2024-05-22 | Sandoz Inc. | $31 | Food and Beverage | In-kind items and services | Cimerli Biological, Ophthalmology | 2024 | |
| 2024-05-01 | Astellas Pharma US Inc | $22 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2024 | |
| 2024-04-23 | Sandoz Inc. | $37 | Food and Beverage | In-kind items and services | Cimerli Biological, Ophthalmology | 2024 | |
| 2024-04-10 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-04-03 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2024 | |
| 2024-02-28 | Genentech USA, Inc. | $26 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-01-25 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2024 | |
| 2023-12-13 | Genentech USA, Inc. | $18 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-11-15 | Apellis Pharmaceuticals, Inc. | $24 | Food and Beverage | Cash or cash equivalent | Syfovre Drug, Ophthalmology | 2023 | |
| 2023-10-26 | Coherus Oncology, Inc. | $14 | Food and Beverage | In-kind items and services | Cimerli Biological, Ophthalmology | 2023 | |
| 2023-10-18 | Astellas Pharma US Inc | $19 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-16 | Biogen, Inc. | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-13 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-07-27 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-07-12 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2023 | |
| 2023-06-07 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-05-15 | Bausch & Lomb Americas Inc. | $18 | Food and Beverage | In-kind items and services | XIPERE Drug, Ophthalmology | 2023 | |
| 2023-05-04 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-03-24 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2023 | |
| 2023-03-15 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-02-15 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-02-01 | Biogen, Inc. | $24 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-01-11 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2022-12-31 | F. Hoffmann-La Roche AG | $2,478 | Research payment | In-kind items and services | Lucentis Biological, Ophthalmology | PDS PHASE 3 ARCHWAY | 2022 |
| 2022-11-11 | Biogen, Inc. | $19 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-11-09 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2022 | |
| 2022-10-06 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2022 | |
| 2022-10-05 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-09-08 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-09-07 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2022 | |
| 2022-08-25 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2022 | |
| 2022-06-30 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2022 | |
| 2022-06-29 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2022 | |
| 2022-06-01 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-05-05 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2022 | |
| 2022-04-27 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-04-20 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-04-13 | US Retina LLC | $31,795 | Current or prospective ownership or investment interest | Cash or cash equivalent | 2022 | ||
| 2022-04-12 | US Retina LLC | $4,769 | Current or prospective ownership or investment interest | Cash or cash equivalent | 2022 | ||
| 2022-03-24 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2022 | |
| 2022-03-23 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2022 | |
| 2022-02-24 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2021-12-31 | US Retina LLC | $302,155 | Acquisitions | Cash or cash equivalent | 2021 | ||
| 2021-11-17 | Allergan, Inc. | $15 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-28 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2021 | |
| 2021-05-11 | US Retina LLC | $88,988 | Current or prospective ownership or investment interest | Cash or cash equivalent | 2021 | ||
| 2021-05-11 | US Retina LLC | $41,101 | Current or prospective ownership or investment interest | Cash or cash equivalent | 2021 | ||
| 2021-05-06 | US Retina LLC | $13,496 | Current or prospective ownership or investment interest | Cash or cash equivalent | 2021 | ||
| 2021-05-06 | US Retina LLC | $6,233 | Current or prospective ownership or investment interest | Cash or cash equivalent | 2021 | ||
| 2021-05-05 | Allergan, Inc. | $20 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-02-23 | Genentech USA, Inc. | $13 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2021 | |
| 2021-01-28 | Allergan, Inc. | $19 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2020-03-13 | US Retina LLC | $71,324 | Current or prospective ownership or investment interest | Cash or cash equivalent | 2020 | ||
| 2020-03-13 | US Retina LLC | $11,408 | Current or prospective ownership or investment interest | Cash or cash equivalent | 2020 | ||
| 2020-02-13 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2020 | |
| 2020-01-10 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2020 | |
| 2019-12-11 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2019 | |
| 2019-11-13 | Novartis Pharmaceuticals Corporation | $11 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2019 | |
| 2019-11-07 | Allergan, Inc. | $16 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2019 | |
| 2019-10-30 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2019 | |
| 2019-10-16 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2019 | |
| 2019-10-02 | Allergan, Inc. | $16 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2019 | |
| 2019-08-28 | Allergan, Inc. | $16 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2019 | |
| 2019-08-15 | Genentech, Inc. | $21 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2019 | |
| 2019-08-07 | Genentech USA, Inc. | $16 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2019 | |
| 2019-06-29 | Genentech, Inc. | $239 | Food and Beverage | In-kind items and services | Non-Covered Product Drug, None | 2019 | |
| 2019-06-28 | Genentech, Inc. | $449 | Travel and Lodging | In-kind items and services | Non-Covered Product Drug, None | 2019 | |
| 2019-06-28 | Genentech, Inc. | $431 | Travel and Lodging | In-kind items and services | Non-Covered Product Drug, None | 2019 | |
| 2019-06-28 | Genentech, Inc. | $116 | Food and Beverage | In-kind items and services | Non-Covered Product Drug, None | 2019 | |
| 2019-06-28 | Genentech, Inc. | $46 | Food and Beverage | Cash or cash equivalent | Non-Covered Product Drug, None | 2019 | |
| 2019-06-28 | Genentech, Inc. | $44 | Travel and Lodging | Cash or cash equivalent | Non-Covered Product Drug, None | 2019 | |
| 2019-05-29 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2019 | |
| 2019-03-28 | Allergan, Inc. | $16 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2019 | |
| 2019-02-21 | US Retina LLC | $93,536 | Current or prospective ownership or investment interest | Stock option | 2019 | ||
| 2019-02-21 | US Retina LLC | $14,960 | Current or prospective ownership or investment interest | Stock option | 2019 | ||
| 2019-02-21 | Genentech USA, Inc. | $16 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2019 | |
| 2019-02-14 | Regeneron Healthcare Solutions, Inc. | $14 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2019 | |
| US Retina LLC | $1,652,946 interest valued $1,927,151 | Ownership or investment interest | Physician Covered Recipient | Membership Interest | 2024 | ||
| US Retina LLC | $652,199 interest valued $1,096,912 | Ownership or investment interest | Physician Covered Recipient | Membership Interest | 2024 | ||
| US Retina LLC | $183,544 interest valued $274,206 | Ownership or investment interest | Physician Covered Recipient | Membership Interest | 2023 | ||
| US Retina LLC | $72,428 interest valued $444,713 | Ownership or investment interest | Physician Covered Recipient | Membership Interest | 2023 | ||
| US Retina LLC | $0 interest valued $197,400 | Ownership or investment interest | Physician Covered Recipient | Shares | 2020 | ||
| US Retina LLC | $0 interest valued $500,266 | Ownership or investment interest | Physician Covered Recipient | Shares | 2022 | ||
| US Retina LLC | $0 interest valued $1,234,157 | Ownership or investment interest | Physician Covered Recipient | Shares | 2021 | ||
| US Retina LLC | $0 interest valued $197,400 | Ownership or investment interest | Physician Covered Recipient | Shares | 2019 | ||
| US Retina LLC | $0 interest valued $1,234,157 | Ownership or investment interest | Physician Covered Recipient | Shares | 2019 | ||
| US Retina LLC | $0 interest valued $197,400 | Ownership or investment interest | Physician Covered Recipient | Shares | 2021 | ||
| US Retina LLC | $0 interest valued $197,400 | Ownership or investment interest | Physician Covered Recipient | Shares | 2022 | ||
| US Retina LLC | $0 interest valued $1,234,157 | Ownership or investment interest | Physician Covered Recipient | Shares | 2020 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-11 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $24,462 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2025 |
| 2025-12-08 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $93,779 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2025 |
| 2025-10-17 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $17,304 | Port Delivery System of Ranibizumab Extension Study | 2025 |
| 2025-10-16 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $2,559 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2025 |
| 2025-09-11 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $960 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2025 |
| 2025-07-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $16,620 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2025 |
| 2025-07-24 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $2,666 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2025 |
| 2025-07-07 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $23,581 | Port Delivery System of Ranibizumab Extension Study | 2025 |
| 2025-06-25 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $23,945 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2025 |
| 2025-06-02 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $26,545 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2025 |
| 2025-06-02 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $100 | Port Delivery System of Ranibizumab Extension Study | 2025 |
| 2025-03-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $5,512 | Port Delivery System of Ranibizumab Extension Study | 2025 |
| 2025-03-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $7,530 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2025 |
| 2025-02-18 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $19,839 | Port Delivery System of Ranibizumab Extension Study | 2025 |
| 2025-02-18 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $25,475 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2025 |
| 2025-01-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $181 | Port Delivery System of Ranibizumab Extension Study | 2025 |
| 2025-01-21 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $2,920 | Port Delivery System of Ranibizumab Extension Study | 2025 |
| 2024-12-12 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $20,800 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2024 |
| 2024-12-11 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $19,969 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-11-06 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $33,612 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2024 |
| 2024-10-30 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $185 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-10-10 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $10,746 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-10-08 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $2,887 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2024 |
| 2024-09-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $2,339 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2024 |
| 2024-09-04 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $9,939 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2024 |
| 2024-08-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $10,968 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2024 |
| 2024-08-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $1,206 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2024 |
| 2024-08-15 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $2,473 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-07-05 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $13,491 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-06-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $871 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2024 |
| 2024-06-24 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $16,614 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2024 |
| 2024-05-29 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $300 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-05-22 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $2,544 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-05-22 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $792 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-05-20 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $22,046 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-03-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $20,201 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2024 |
| 2024-03-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $20 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-03-12 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $6,699 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2024 |
| 2024-03-12 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $162 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-03-12 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $365 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2024-01-08 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $12,525 | Port Delivery System of Ranibizumab Extension Study | 2024 |
| 2023-12-21 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $15,525 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-11-21 | Genentech, Inc. | Southern Vitreoretinal Associates | $3,322 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-11-17 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $72 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-11-16 | Genentech, Inc. | Southern Vitreoretinal Associates | $30,264 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-11-16 | Genentech, Inc. | Southern Vitreoretinal Associates | $10,469 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-11-10 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $365 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-11-06 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $848 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-10-24 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $144 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-10-24 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $12,405 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-10-23 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $2,544 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-10-19 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $1,669 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-10-17 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $500 | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION | 2023 |
| 2023-09-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $11,934 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-09-26 | Genentech, Inc. | Southern Vitreoretinal Associates | $1,926 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-09-21 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $14,499 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-09-01 | Genentech, Inc. | Southern Vitreoretinal Associates | $13,618 | Ph 2 Open label extension of aHtra1 in GA | 2023 |
| 2023-08-03 | Genentech, Inc. | Southern Vitreoretinal Associates | $101 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-08-03 | Genentech, Inc. | Southern Vitreoretinal Associates | $505 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-08-02 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $7,214 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-08-01 | Genentech, Inc. | Southern Vitreoretinal Associates | $960 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-07-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $3,285 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-07-27 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $9,587 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-07-19 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $4,015 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-07-19 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $4,745 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-07-12 | Genentech, Inc. | Southern Vitreoretinal Associates | $131 | Ph 2 Open label extension of aHtra1 in GA | 2023 |
| 2023-07-12 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $4,975 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-07-11 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $5,027 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-07-10 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $21,377 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-06-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $2,500 | Ph 2 Open label extension of aHtra1 in GA | 2023 |
| 2023-06-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $5,000 | Ph 2 Open label extension of aHtra1 in GA | 2023 |
| 2023-06-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $1,424 | Ph 2 Open label extension of aHtra1 in GA | 2023 |
| 2023-06-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $116 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-06-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $3,321 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-06-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $18,494 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-06-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $20,203 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-06-20 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $700 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-06-20 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $5,000 | MAD to assess the safety tolerability and PK PD in nAMD patients | 2023 |
| 2023-06-20 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $3,872 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-06-15 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $1,008 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-06-15 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $1,111 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-06-15 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $4,000 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-06-08 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $62,594 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-05-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $3,021 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-05-23 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $3,000 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-05-23 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $500 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-05-04 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $5,500 | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION | 2023 |
| 2023-04-18 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $29,869 | Phase 2 of RO7171009 in GA | 2023 |
| 2023-03-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $23,490 | Port Delivery System of Ranibizumab Extension Study | 2023 |
| 2023-03-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $29,013 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023 |
| 2023-03-15 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $8,055 | Ph 2 Open label extension of aHtra1 in GA | 2023 |
| 2023-01-26 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC PA | $3,852 | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION | 2023 |
| 2022-12-19 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $12,170 | PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY | 2022 |
| 2022-12-16 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $13,708 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2022 |
| 2022-10-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $5,919 | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION | 2022 |
| 2022-10-25 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $10,701 | PHASE 2 OF RO7171009 IN GA | 2022 |
| 2022-10-19 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOCIA | $24,721 | PH 2 OPEN LABEL EXTENSION OF AHTRA1 IN GA | 2022 |
| 2022-09-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $36,199 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2022 |
| 2022-09-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $23,164 | PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY | 2022 |
| 2022-09-28 | Genentech, Inc. | SOUTHERN VITREORETINAL ASSOC | $111 | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Dothan, AL, county Houston County, AL, state Alabama; placed by its city name.
| Measure | Place (city or town) Dothan, AL | County Houston County, AL | State Alabama |
|---|---|---|---|
| Population B01003 | 71,514 | 108,140 | 5,086,768 |
| Population, 2020 census P1 | 71,072 | 107,202 | 5,024,279 |
| Median age B01002 | 40.2 | 40.3 | 39.3 |
| Under 18 B01001 | 22.6% | 22.9% | 22.2% |
| 65 and over B01001 | 18.8% | 18.7% | 17.8% |
| Households B11001 | 29,351 | 43,302 | 1,997,247 |
| Foreign born B05002 | 3.7% | 3.1% | 4.0% |
| Median household income B19013 | $55,792 | $58,626 | $63,999 |
| Median family income B19113 | $76,315 | $76,243 | $83,032 |
| Per capita income B19301 | $35,321 | $34,005 | $36,087 |
| Poverty rate B17001 | 19.3% | 17.5% | 15.6% |
| Unemployment rate B23025 | 4.3% | 4.5% | 4.7% |
| Civilian labor force B23025 | 32,750 | 49,539 | 2,367,787 |
| Mean commute (minutes) B08013 | 20.4 | 22.1 | 25.5 |
| Bachelor's degree or higher B15003 | 27.6% | 23.0% | 28.4% |
| Housing units B25001 | 33,734 | 50,158 | 2,337,265 |
| Owner-occupied B25003 | 57.1% | 63.8% | 70.2% |
| Renters B25003 | 42.9% | 36.2% | 29.8% |
| Median home value B25077 | $194,000 | $183,300 | $209,900 |
| Median gross rent B25064 | $960 | $945 | $1,007 |
| White, not Hispanic B03002 | 54.4% | 63.4% | 63.4% |
| Black B03002 | 35.7% | 27.1% | 25.6% |
| Hispanic or Latino B03002 | 4.8% | 4.6% | 5.6% |
| Asian B03002 | 1.5% | 1.1% | 1.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 3.5% in Sep 2026 (2.8% a year earlier); per capita personal income $59,754 in 2025, up 30% in five years (+4.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Dothan, AL.
Comments